Leadership

R. Wilder Scott is the founding Chief Technology Officer of Mesintel Therapeutics. Wilder has spearheaded multi-omics data collection and analysis efforts, and established several novel disease models. He is also leading our efforts on implementing new data analysis pipelines and machine learning approaches. Wilder completed his BSc at the University of Saskatchewan. He received his PhD from the University of British Columbia, studying fibroblast function in tissue regeneration, followed by post-doctoral training at the School of Biomedical Engineering (UBC).